The majority of currently used therapeutics are small molecule-based and utilize occupancy-
driven pharmacology as the mode of action (MOA), in which the protein function is …

PROTACs-induced targeted protein degradation has emerged as a novel therapeutic
strategy in drug development and attracted the favor of academic institutions, large …

Proteolysis‐targeting chimeric molecules (PROTACs) represent an emerging technique that
is receiving much attention for therapeutic intervention. The mechanism is based on the …

Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

There are several challenges towards the development and clinical use of small molecule
inhibitors, which are currently the main type of targeted therapies towards intracellular …

Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to
degrade target proteins by hijacking the ubiquitin–proteasome system, have the potential to …

Proteolysis targeting chimera (PROTAC) technology is a chemical protein knockdown
approach that degrades protein by hijacking the cellular ubiquitin-proteasome system to …

Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the
accessible binding sites to achieve prolonged occupancy and influence protein functions …

A new generation of heterobifunctional small molecules, termed proteolysis targeting
chimeras (PROTACs), targets proteins for degradation through recruitment to E3 ligases and …

Proteolysis targeting chimeras (PROTAC) represents a new type of small molecule induced
protein degradation technology that has emerged in recent years. PROTAC uses …